alixorexton

all catalysts(0)

nothing on the calendar yet

News(6)

• With pioneering ADHD data, Alkermes eyes orexin agonist as potential ‘company changer’
  Following Takeda’s historic approval of the first orexin agonist with its narcolepsy treatment Orzeyful, Alkermes has followed up with pioneering data that looks to take the hyped drug class out of…
  fiercebiotech · 15d ago
• ‘A neuroscience revolution’: The GLP-like race to keep us awake and make billions doing it
  As the hype around the vast medical potential of GLP-1 drugs continues unabated, another peptide is starting to make its own mark.
  fiercebiotech · 1mo ago
• Takeda leads wave of orexin drugs with potential to upend narcolepsy market
  The FDA’s August approval of Takeda’s Orzeyful for treating the full set of narcolepsy symptoms initiated a new era in the sleep market.
  biospace · 1mo ago
• Takeda approval ushers in new wave of sleep drugs
  An FDA nod mostly clears the way for Orzeyful to enter, by Wall Street estimates, a multibillion-dollar market for drugs that boost “orexin” proteins.
  biopharma_dive · 1mo ago
• 4 potential biotech M&A targets, plus a pretty sure bet from J&J
  Pharma is definitely interested in making more deals. But what biotechs will come under the magnifying glass? BioSpace takes a look at companies that analysts see as near-term targets for buyouts.
  biospace · 1mo ago
• Alkermes’ incoming CEO has a plan to outplay Lilly and Takeda
  Blair Jackson says the next 12 months may be the most important in Alkermes’ history, as the brain drugmaker races to join an “orexin” market that analysts see as a multibillion-dollar opportunity.
  biopharma_dive · 3mo ago